Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom

Cost Effectiveness and Resource Allocation

Research

Jane Wolstenholme¹  Oliver Rivero-Arias¹  Alastair Gray¹ 

[1] Health Economics Research Centre, Department of Public Health, University of Oxford, UK;

关键词: National Health Service;    Informal Care;    Aneurysmal Subarachnoid Haemorrhage;    Hospital Episode Statistics;    aSAH Patient;   

DOI  :  10.1186/1478-7547-8-6

 received in 2009-04-22, accepted in 2010-04-27,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundTo estimate life years and quality-adjusted life years (QALYs) lost and the economic burden of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom including healthcare and non-healthcare costs from a societal perspective.MethodsAll UK residents in 2005 with aSAH (International Classification of Diseases 10th revision (ICD-10) code I60). Sex and age-specific abridged life tables were generated for a general population and aSAH cohorts. QALYs in each cohort were calculated adjusting the life tables with health-related quality of life (HRQL) data. Healthcare costs included hospital expenditure, cerebrovascular rehabilitation, primary care and community health and social services. Non-healthcare costs included informal care and productivity losses arising from morbidity and premature death.ResultsA total of 80,356 life years and 74,807 quality-adjusted life years were estimated to be lost due to aSAH in the UK in 2005. aSAH costs the National Health Service (NHS) £168.2 million annually with hospital inpatient admissions accounting for 59%, community health and social services for 18%, aSAH-related operations for 15% and cerebrovascular rehabilitation for 6% of the total NHS estimated costs. The average per patient cost for the NHS was estimated to be £23,294. The total economic burden (including informal care and using the human capital method to estimate production losses) of a SAH in the United Kingdom was estimated to be £510 million annually.ConclusionThe economic and disease burden of aSAH in the United Kingdom is reported in this study. Decision-makers can use these results to complement other information when informing prevention policies in this field and to relate health care expenditures to disease categories.

【 授权许可】

CC BY   
© Rivero-Arias et al; licensee BioMed Central Ltd. 2010